Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
Mineralys Therapeutics (NASDAQ: MLYS) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Monday, November 10, 2025.
The company will host a conference call and live webcast on Monday, November 10, 2025 at 4:30 p.m. ET. Domestic dial-in is 1-877-704-4453, international dial-in is 1-201-389-0920, and the conference ID is 13756051. The webcast will be available on the company’s Investor Relations "News & Events" page.
Mineralys Therapeutics (NASDAQ: MLYS) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Monday, November 10, 2025.
The company will host a conference call and live webcast on Monday, November 10, 2025 at 4:30 p.m. ET. Domestic dial-in is 1-877-704-4453, international dial-in is 1-201-389-0920, and the conference ID is 13756051. The webcast will be available on the company’s Investor Relations "News & Events" page.
Mineralys Therapeutics (NASDAQ: MLYS) informará los resultados financieros del tercer trimestre de 2025 para el periodo terminado el 30 de septiembre de 2025 después del cierre del mercado el lunes 10 de noviembre de 2025.
La empresa celebrará una conferencia telefónica y una transmisión en vivo el lunes 10 de noviembre de 2025 a las 4:30 p.m. hora del Este. El número de marcación nacional es 1-877-704-4453, internacional 1-201-389-0920, y el ID de la conferencia es 13756051. La transmisión web estará disponible en la página de Relaciones con Inversores de la empresa "News & Events".
Mineralys Therapeutics (NASDAQ: MLYS)은 2025년 9월 30일자로 종료되는 2025년 3분기 재무 실적을 2025년 11월 10일 월요일 장 마감 후 발표합니다.
회사는 2025년 11월 10일 월요일 오후 4시 30분(동부 표준시)에 컨퍼런스 콜과 생방송을 개최합니다. 국내 다이얼 인은 1-877-704-4453, 국제 다이얼 인은 1-201-389-0920, 컨퍼런스 ID는 13756051입니다. webcast는 회사의 투자자 관계 페이지의 News & Events에서 확인할 수 있습니다.
Mineralys Therapeutics (NASDAQ : MLYS) communiquera les résultats financiers du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025 après la clôture du marché le lundi 10 novembre 2025.
La société organisera une conférence téléphonique et une webdiffusion en direct le lundi 10 novembre 2025 à 16h30, heure de l'Est. Le numéro d’accès national est 1-877-704-4453, l’accès international est 1-201-389-0920, et l’identifiant de la conférence est 13756051. La webdiffusion sera disponible sur la page Relations Investisseurs "News & Events" de la société.
Mineralys Therapeutics (NASDAQ: MLYS) wird die Finanzergebnisse des dritten Quartals 2025 für den Zeitraum bis zum 30. September 2025 nach Börsenschluss am Montag, dem 10. November 2025 bekannt geben.
Das Unternehmen wird am Montag, dem 10. November 2025 um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Live-Webcast veranstalten. Inlandsnummer lautet 1-877-704-4453, internationale Nummer 1-201-389-0920, und die Konferenz-ID ist 13756051. Der Webcast wird auf der Investor-Relations-Seite des Unternehmens unter News & Events verfügbar sein.
Mineralys Therapeutics (NASDAQ: MLYS) ستعلن عن نتائجها المالية للربع الثالث من عام 2025 للفترة المنتهية في 30 سبتمبر 2025 بعد إغلاق السوق يوم الاثنين 10 نوفمبر 2025.
ستستضيف الشركة مكالمة مؤتمر وبثاً مباشراً يوم الاثنين 10 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة. رقم الاتصال المحلي هو 1-877-704-4453، ورقم الاتصال الدولي هو 1-201-389-0920، ومعرّف المؤتمر هو 13756051. سيكون البث متاحاً على صفحة العلاقات مع المستثمرين للشركة "News & Events".
- None.
- None.
RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2025, after the financial markets close on Monday, November 10, 2025.
| Monday, November 10th @ 4:30 p.m. ET | |
| Domestic: | 1-877-704-4453 |
| International: | 1-201-389-0920 |
| Conference ID: | 13756051 |
| Webcast: | Webcast Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) report Q3 2025 results?
What time is the Mineralys Therapeutics (MLYS) Q3 2025 conference call?
How do I join the Mineralys Therapeutics (MLYS) conference call on November 10, 2025?
Where can investors find the Mineralys Therapeutics (MLYS) webcast for the Q3 2025 call?
What period do the Q3 2025 results for Mineralys Therapeutics (MLYS) cover?
